LivaNova PLC
NASDAQ:LIVN

Watchlist Manager
LivaNova PLC Logo
LivaNova PLC
NASDAQ:LIVN
Watchlist
Price: 51.32 USD -0.74% Market Closed
Market Cap: 2.8B USD
Have any thoughts about
LivaNova PLC?
Write Note

LivaNova PLC
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LivaNova PLC
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
LivaNova PLC
NASDAQ:LIVN
Net Change in Cash
$133.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
21%
Smith & Nephew PLC
LSE:SN
Net Change in Cash
$362m
CAGR 3-Years
-30%
CAGR 5-Years
55%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Net Change in Cash
ÂŁ655k
CAGR 3-Years
-45%
CAGR 5-Years
-25%
CAGR 10-Years
-22%
Angle PLC
LSE:AGL
Net Change in Cash
-ÂŁ4.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Net Change in Cash
-ÂŁ1.6m
CAGR 3-Years
66%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Net Change in Cash
-$1.1m
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LivaNova PLC
Glance View

Market Cap
2.8B USD
Industry
Health Care

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The firm operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

LIVN Intrinsic Value
81.64 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is LivaNova PLC's Net Change in Cash?
Net Change in Cash
133.9m USD

Based on the financial report for Sep 30, 2024, LivaNova PLC's Net Change in Cash amounts to 133.9m USD.

What is LivaNova PLC's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
21%

Over the last year, the Net Change in Cash growth was 406%.

Back to Top